“…In MeCP2 ChIP-Seq in MDA-MB-468 cells, we found that MeCP2 binds to multiple novel targets not previously associated with MeCP2 function in the context of breast cancer. Some of these included the following genes: a) SSU72 Homolog, RNA Polymerase II CTD Phosphatase (SSU72), a protein phosphatase that catalyzes the dephosphorylation of the C-terminal domain of RNA polymerase II ( 66 ); b) CAPN2 (Calpain 2), a calcium-sensitive cysteine protease ( 67 ); c) Plexin B2 (PLXNB2), a class B transmembrane receptor that participates in axon guidance and cell migration in response to semaphorins ( 68 ); d) Zinc Finger SWIM-Type Containing 4 (ZSWIM4); e) RUNX Family Transcription Factor 3 (RUNX3) a transcription factor that functions as a tumor suppressor and is frequently deleted or transcriptionally silenced in cancer ( 69 , 70 ), and f) Solute Carrier Family 45 Member 4 (SLC45A4) ( Figure 1B ). Additionally, in MCF7 some of the notable genes included a) Ubiquitin Specific Peptidase 34 (USP34), a ubiquitin hydrolase that removes conjugated ubiquitin from AXIN1 and AXIN2, acting as a regulator of Wnt signaling pathway ( 71 ); b) Maltase–Glucoamylase (MGAM), an enzyme that plays a role in the digestion of starch ( 72 ); c) GDP-Mannose 4,6-Dehydratase (GMDS), an enzyme that participates in the synthesis of GDP-fucose from GDP-mannose ( 73 ); d) Solute Carrier Family 45 Member 4 (SLC45A4); e) CCDC26 Long Non-Coding RNA (CCDC26), a lncRNA class associated with Malignant Glioma and Astrocytoma ( 74 , 75 ); and f) Sidekick Cell Adhesion Molecule 1 (SDK1) ( Figure 1C ).…”